Breast cancer accounts for 18% of all cancers in women, making it the foremost cause of cancer-related deaths in women. The prevalence rates for breast cancer in seven major markets (France, Germany, Italy, Spain, UK, US and Japan) grew to over 2.14 million in 2016.
Currently, routine mammography is the most commonly used method for early detection of breast cancer. Therefore, early diagnosis and treatment of breast cancer could play a monumental role in reducing deaths. Most of the drugs available for the treatment of breast cancers, target either the endocrine (estrogen; ER) or growth factor ((ErbB-1, ErbB-2 [human epidermal growth factor receptor 2; HER2], ErbB-3 and ErbB-4) receptors for therapy. However, emerging resistance to endocrine and therapies targeted against HER2 receptors has resulted in limited treatment outcome, poor prognosis and lower patient survival rates. Moreover, there are currently no targeted therapies available for the treatment of Triple-Negative Breast Cancer, which lack these receptors, and is the most aggressive type of breast cancer with a prevalence rate of 15-20%. Additionally, the cancer cells find a roundabout i.e., if one biochemical pathway for growth is blocked, it activates a different, equally effective pathway, when treated with therapies targeting the growth kinase receptors and their intermediates. This is why a radically different approach for the treatment of breast cancer is imperative, one that identifies molecular targets that are non-receptor based and directly targets the cell proliferation machinery of the cancer cells.
We have identified a unique biomarker for Triple Negative Breast Cancer that is:
- Endocrine and growth receptor independent.
- Directly involved in all stages of Cell Proliferation; including DNA replication, Mitosis & Cytokinesis.
- A biomarker for all subtypes of breast cancer as well as other gynacological cancers.
- A biomarker for blood cancers such as acute and chronic myeloid leukemia.
Inhibition of this biomarker selectively kills cancer cells by apoptosis. Hence, this biomarker offers a dual benefit of developing therapeutics as well as companion diagnostic kits for breast cancers.